🇺🇸 FDA
Pipeline program

Pimavanserin

ACP-103-046

Phase 3 small_molecule completed

Quick answer

Pimavanserin for Neuropsychiatric Symptoms Related to Neurodegenerative Disease is a Phase 3 program (small_molecule) at ACADIA PHARMACEUTICALS INC with 2 ClinicalTrials.gov record(s).

Program details

Company
ACADIA PHARMACEUTICALS INC
Indication
Neuropsychiatric Symptoms Related to Neurodegenerative Disease
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials